Sign In
Buy CBIO
$17.98
+0.98 (+5.73%)
At Close: Jun 03, 2026
Is a Surprise Coming for Catalyst Biosciences (CBIO) This Earnings Season?
10:31am, Thursday, 06'th May 2021
Catalyst Biosciences (CBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update
08:00am, Thursday, 06'th May 2021
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021 a
Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
04:05pm, Wednesday, 07'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will present a corporate overvie
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update
08:00am, Thursday, 04'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and full-year endin
5 Stocks to Buy Now Trading Under $10 With Plenty of Upside Potential
06:15am, Saturday, 13'th Feb 2021
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock
04:01pm, Thursday, 11'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced that in connection with its previously announced public offe
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented positive pre-clinical data from its Marzeptacog alfa (activated) – MarzAA, pr
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
04:01pm, Friday, 29'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced the closing of an underwritten public offering of 8,700,000
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
08:00am, Wednesday, 27'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO (the “Company”) today announced the pricing of an underwritten public offering of 8,700,000 s
Catalyst Biosciences Announces Proposed Public Offering of Common Stock
04:04pm, Tuesday, 26'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it is offering shares of its common stock in an underwritten public offeri
Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress
08:00am, Wednesday, 20'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the European Association for Haemophilia and All
Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital
08:00am, Friday, 15'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hos
Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
08:00am, Monday, 07'th Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62nd Annual American Society of Hematology (ASH) meeting, held
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
04:02pm, Thursday, 03'rd Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company's systemic com
Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next
07:18pm, Friday, 13'th Nov 2020
Catalyst Biosciences is targeting the hemophilia space with a strong candidate treating types A and B with inhibitors, and second targeting type B. Current standard of care NovoSeven is administered i
